Esperion, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Paul Choi from Goldman Sachs maintained a Hold rating on the stock and has a $3.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paul Choi has given his Hold rating due to a combination of factors tied to Esperion’s newly announced deal and its execution risks. He views the planned acquisition of Corstasis and its intranasal diuretic Enbumyst as strategically consistent with Esperion’s long‑term vision to broaden its cardiovascular portfolio, but notes that investors are skeptical given recent share underperformance and the crowded congestive heart failure segment, including competition from MannKind.
Choi also highlights that the transaction structure, reliant on upfront cash, milestone payments, Japanese royalty monetization, and credit facilities, adds financial complexity while commercial benefits will be gradual, with more meaningful sales expected only after full integration in 3Q. Given these uncertainties and the fact that his model does not yet incorporate Enbumyst until the deal formally closes, he concludes that the risk‑reward profile is balanced at current levels, supporting a Hold rather than a more decisive rating change.
ESPR’s price has also changed moderately for the past six months – from $2.430 to $2.910, which is a 19.75% increase.